Elacestrant: Side Effects, Uses & Monitoring

Facts extracted from current FDA product labeling for Elacestrant. Educational only — not medical advice.

Labeled uses

ORSERDU is indicated for the treatment of postmenopausal women or adult men with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)‑negative, ESR1 -mutated advanced or metastatic breast cancer, as detected by an FDA-authorized test [see Dosage and Administration (2.1 )] , with disease progression following at least one line of endocrine therapy.

Source: FDA labeling via NIH DailyMed (set aa66ae5c…). Not affiliated with FDA or NIH.

Medical disclaimer: Always consult a qualified healthcare professional about any medication.

Ratings summarize government-reported measures — they don't capture your personal needs. Visit the facility, ask about staffing and services, and use CMS checklists. This profile is informational only and is not a recommendation.